Randomized Phase II Study of Neoadjuvant Combined-Modality Chemoradiation for Distal Rectal Cancer: Radiation Therapy Oncology Group Trial 0012
- 1 February 2006
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (4), 650-655
- https://doi.org/10.1200/jco.2005.03.6095
Abstract
Purpose: To evaluate the rate of pathologic complete response and toxicity of neoadjuvant chemoradiation for advanced T3/T4 distal rectal cancers in a randomized phase II study Patients and Methods: Patients with clinical T3/T4 distal rectal cancers were randomly assigned in a phase II study to receive combined neoadjuvant chemoradiotherapy followed by surgical resection. Patients were randomly assigned to receive continuous venous infusion (CVI) fluorouracil (FU) 225 mg/m2 per day, 7 days per week, plus pelvic hyperfractionated radiation 55.2 to 60 Gy at 1.2 Gy bid (arm 1) or CVI FU 225 mg/m2 per day Monday to Friday, 120 hours per week plus irinotecan 50 mg/m2 once weekly for 4 weeks plus pelvic radiation therapy 50.4 to 54 Gy at 1.8 Gy per day (arm 2). Surgery was performed 4 to 10 weeks after completion of neoadjuvant therapy. The primary end point of this study was pathologic complete response (pCR). Secondary end points included acute and late normal tissue morbidity. Results: A total of 106 patients were entered onto the study, with 103 assessable for response. The overall resectability rate was 93%. The median time to surgery was 7 weeks. Tumor downstaging was observed in 78% of patients in both arms. The pCR rate for all assessable patients was 26% in each arm. For patients who had surgery, the pCR rate was also the same (28%) in both arms. Acute and late toxicity was also similar. Grade 3 and 4 acute hematologic and nonhematologic toxicity occurred in 13% and 38% in arm 1 and 12% and 45% in arm 2, respectively. Conclusion: Although the overall complete response rate and toxicity seems similar in both arms, this is the first multi-institutional study to establish a relatively high (28%) pCR rate after neoadjuvant therapy.Keywords
This publication has 31 references indexed in Scilit:
- Preoperative versus Postoperative Chemoradiotherapy for Rectal CancerThe New England Journal of Medicine, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Improved Survival with Preoperative Radiotherapy in Resectable Rectal CancerThe New England Journal of Medicine, 1997
- Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancerThe Lancet, 1996
- Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: Reduction in local treatment failureEuropean Journal of Cancer, 1994
- The Long-Term Effect of Adjuvant Postoperative Chemoradiotherapy for Rectal Carcinoma on Bowel FunctionAnnals of Surgery, 1994
- Effective Surgical Adjuvant Therapy for High-Risk Rectal CarcinomaThe New England Journal of Medicine, 1991
- Preoperative Radiotherapy as Adjuvant Treatment in Rectal CancerAnnals of Surgery, 1988
- Survival after Postoperative Combination Treatment of Rectal CancerThe New England Journal of Medicine, 1986
- Preoperative radiation and surgery for cancer of the rectum: Veterans administration surgical oncology group trial IICancer, 1986